Peer-Reviewed Study Reports on New Blood Test for Early Breast Cancer Detection

Why it matters locally: The development of a new blood test for early breast cancer detection could eventually impact healthcare access and services provided through institutions like NYC Health + Hospitals/Kings County Emergency Room, potentially offering new screening options for the state's significant population.

---

SAINT PAUL, Minn. – Researchers published a new peer-reviewed study detailing the capabilities of a blood test for early-stage breast cancer detection. The study appeared in a scientific journal on July 30, 2026. The authors, affiliated with Astrin Biosciences, reported the test demonstrated a sensitivity exceeding 92% and a specificity exceeding 92%. These metrics, they indicate, surpass the performance of current supplemental screening standards. Astrin Biosciences, a company focused on cancer detection and treatment, developed the test. Researchers developed the blood test using deep proteomics, a method involving the large-scale study of proteins. The company states this technology enables the analysis of numerous proteins within a blood sample. This analysis aims to identify early indicators of breast cancer.